Annual report pursuant to Section 13 and 15(d)

Note 2 - Acquisitions - Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed Pending Final Valuation of Intangible Assets (Details)

v3.5.0.2
Note 2 - Acquisitions - Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed Pending Final Valuation of Intangible Assets (Details) - USD ($)
 12 Months Ended
Jul. 08, 2015
Apr. 30, 2014
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2014
Zephyrus [Member] | In Process Research and Development [Member]          
Intangible Assets:          
Intangible assets     $ 7,400,000    
Zephyrus [Member] | Developed Technology Rights [Member]          
Intangible Assets:          
Intangible assets        
Zephyrus [Member] | Trade Names [Member]          
Intangible Assets:          
Intangible assets        
Zephyrus [Member] | Customer Relationships [Member]          
Intangible Assets:          
Intangible assets        
Zephyrus [Member] | Noncompete Agreements [Member]          
Intangible Assets:          
Intangible assets        
Zephyrus [Member]          
Current assets     86,000    
Equipment     32,000    
Other long-term assets        
Intangible Assets:          
Goodwill     6,878,000    
Total assets acquired     14,396,000    
Liabilities     54,000    
Deferred income taxes, net     2,812,000    
Net assets     11,530,000    
Less fair-value of previous investment        
Net assets acquired     11,530,000    
Payments to Acquire Businesses, Net of Cash Acquired     8,030,000    
Business Combination, Consideration Transferred, Liabilities Incurred     0    
Contingent consideration payable     3,500,000    
Business Combination, Consideration Transferred     11,530,000    
Cliniqa [Member] | In Process Research and Development [Member]          
Intangible Assets:          
Intangible assets        
Cliniqa [Member] | Developed Technology Rights [Member]          
Intangible Assets:          
Intangible assets     18,000,000    
Cliniqa [Member] | Trade Names [Member]          
Intangible Assets:          
Intangible assets     1,100,000    
Cliniqa [Member] | Customer Relationships [Member]          
Intangible Assets:          
Intangible assets     27,000,000    
Cliniqa [Member] | Noncompete Agreements [Member]          
Intangible Assets:          
Intangible assets        
Cliniqa [Member]          
Current assets     11,926,000    
Equipment     1,436,000    
Other long-term assets     58,000    
Intangible Assets:          
Goodwill     42,669,000    
Total assets acquired     102,189,000    
Liabilities     1,508,000    
Deferred income taxes, net     17,793,000    
Net assets     82,888,000    
Less fair-value of previous investment        
Net assets acquired     82,888,000    
Payments to Acquire Businesses, Net of Cash Acquired $ 83,000,000   82,888,000    
Business Combination, Consideration Transferred, Liabilities Incurred     0    
Contingent consideration payable        
Business Combination, Consideration Transferred     82,888,000    
Novus Holdings, LLC [Member] | In Process Research and Development [Member]          
Intangible Assets:          
Intangible assets        
Novus Holdings, LLC [Member] | Developed Technology Rights [Member]          
Intangible Assets:          
Intangible assets     5,010,000    
Novus Holdings, LLC [Member] | Trade Names [Member]          
Intangible Assets:          
Intangible assets     5,300,000    
Novus Holdings, LLC [Member] | Customer Relationships [Member]          
Intangible Assets:          
Intangible assets     14,400,000    
Novus Holdings, LLC [Member] | Noncompete Agreements [Member]          
Intangible Assets:          
Intangible assets        
Novus Holdings, LLC [Member]          
Current assets     10,739,000    
Equipment     1,266,000    
Other long-term assets     40,000    
Intangible Assets:          
Goodwill     28,408,000    
Total assets acquired     65,163,000    
Liabilities     2,166,000    
Deferred income taxes, net     2,875,000    
Net assets     60,122,000    
Less fair-value of previous investment        
Net assets acquired     60,122,000    
Payments to Acquire Businesses, Net of Cash Acquired     60,122,000    
Business Combination, Consideration Transferred, Liabilities Incurred     0    
Contingent consideration payable        
Business Combination, Consideration Transferred     60,122,000 $ 60,000,000  
ProteinSimple [Member] | In Process Research and Development [Member]          
Intangible Assets:          
Intangible assets        
ProteinSimple [Member] | Developed Technology Rights [Member]          
Intangible Assets:          
Intangible assets     39,200,000    
ProteinSimple [Member] | Trade Names [Member]          
Intangible Assets:          
Intangible assets     36,100,000    
ProteinSimple [Member] | Customer Relationships [Member]          
Intangible Assets:          
Intangible assets     101,600,000    
ProteinSimple [Member] | Noncompete Agreements [Member]          
Intangible Assets:          
Intangible assets     200,000    
ProteinSimple [Member]          
Current assets     19,660,000    
Equipment     1,983,000    
Other long-term assets     554,000    
Intangible Assets:          
Goodwill     134,074,000    
Total assets acquired     333,371,000    
Liabilities     11,644,000    
Deferred income taxes, net     21,674,000    
Net assets     300,053,000    
Less fair-value of previous investment        
Net assets acquired     300,053,000    
Payments to Acquire Businesses, Net of Cash Acquired     300,053,000    
Business Combination, Consideration Transferred, Liabilities Incurred     0    
Contingent consideration payable        
Business Combination, Consideration Transferred     300,053,000 300,000,000  
CyVek, Inc. [Member] | In Process Research and Development [Member]          
Intangible Assets:          
Intangible assets        
CyVek, Inc. [Member] | Developed Technology Rights [Member]          
Intangible Assets:          
Intangible assets     20,200,000    
CyVek, Inc. [Member] | Trade Names [Member]          
Intangible Assets:          
Intangible assets     100,000    
CyVek, Inc. [Member] | Customer Relationships [Member]          
Intangible Assets:          
Intangible assets     600,000    
CyVek, Inc. [Member] | Noncompete Agreements [Member]          
Intangible Assets:          
Intangible assets        
CyVek, Inc. [Member]          
Current assets     1,206,000    
Equipment     971,000    
Other long-term assets     19,000    
Intangible Assets:          
Goodwill     91,658,000    
Total assets acquired     114,754,000    
Liabilities     1,965,000    
Deferred income taxes, net     (438,000)    
Net assets     113,227,000    
Less fair-value of previous investment     18,300,000    
Net assets acquired     94,927,000    
Payments to Acquire Businesses, Net of Cash Acquired     59,927,000    
Business Combination, Consideration Transferred, Liabilities Incurred     0    
Contingent consideration payable     35,000,000    
Business Combination, Consideration Transferred     94,927,000 95,000,000  
Bionostics [Member] | In Process Research and Development [Member]          
Intangible Assets:          
Intangible assets        
Bionostics [Member] | Developed Technology Rights [Member]          
Intangible Assets:          
Intangible assets     14,400,000    
Bionostics [Member] | Trade Names [Member]          
Intangible Assets:          
Intangible assets     2,700,000    
Bionostics [Member] | Customer Relationships [Member]          
Intangible Assets:          
Intangible assets     41,000,000    
Bionostics [Member] | Noncompete Agreements [Member]          
Intangible Assets:          
Intangible assets     2,400,000    
Bionostics [Member]          
Current assets     9,605,000    
Equipment     2,180,000    
Other long-term assets        
Intangible Assets:          
Goodwill     56,349,000    
Total assets acquired     128,634,000    
Liabilities     3,007,000    
Deferred income taxes, net     22,478,000    
Net assets     103,149,000    
Less fair-value of previous investment        
Net assets acquired     103,149,000    
Payments to Acquire Businesses, Net of Cash Acquired     103,149,000    
Business Combination, Consideration Transferred, Liabilities Incurred     0    
Contingent consideration payable        
Business Combination, Consideration Transferred     103,149,000   $ 103,000,000
PrimeGene [Member] | In Process Research and Development [Member]          
Intangible Assets:          
Intangible assets        
PrimeGene [Member] | Developed Technology Rights [Member]          
Intangible Assets:          
Intangible assets     2,200,000    
PrimeGene [Member] | Trade Names [Member]          
Intangible Assets:          
Intangible assets     3,000,000    
PrimeGene [Member] | Customer Relationships [Member]          
Intangible Assets:          
Intangible assets     9,100,000    
PrimeGene [Member] | Noncompete Agreements [Member]          
Intangible Assets:          
Intangible assets     322,000    
PrimeGene [Member]          
Current assets     1,272,000    
Equipment     546,000    
Other long-term assets        
Intangible Assets:          
Goodwill     5,518    
Total assets acquired     21,958,000    
Liabilities     887,000    
Deferred income taxes, net     2,310,000    
Net assets     18,761,000    
Less fair-value of previous investment        
Net assets acquired     18,761,000    
Payments to Acquire Businesses, Net of Cash Acquired   $ 6,000,000 6,031,000    
Business Combination, Consideration Transferred, Liabilities Incurred     12,730,000   12,700,000
Contingent consideration payable        
Business Combination, Consideration Transferred     18,761,000   18,700,000
Goodwill     430,882,000 390,638,000 151,473,000
Payments to Acquire Businesses, Net of Cash Acquired     91,423,000 420,102,000 $ 109,180,000
Contingent consideration payable     $ 38,500,000 $ 39,024,000